GlaxoSmithKline Plc:
- Regulatory update - celsentri/selzentry (maraviroc)
- Viiv healthcare withdraws type II variation to European Medicines Agency and Supplemental New Drug Application to FDA for once-daily celsentri/selzentry
- we have concluded that additional data is necessary to establish the efficacy of once-daily dosing of Celsentri/Selzentry.
